汇宇制药：盐酸尼卡地平注射液获得药品注册证书

Core Viewpoint - The company Huiyu Pharmaceutical has received approval from the National Medical Products Administration for its product, Nicardipine Hydrochloride Injection, which is classified as a Class 4 chemical drug and is considered to have passed the consistency evaluation of generic drug quality and efficacy [2] Group 1: Product Approval - The product Nicardipine Hydrochloride Injection is intended for the emergency treatment of abnormal hypertension during surgery and hypertensive emergencies [2] - The approval of the drug registration certificate is a significant milestone for the company, although it is noted that the impact on the company's operating performance in the short term is not substantial [2] Group 2: Market Potential - According to data from Minet, the sales revenue of Nicardipine Hydrochloride Injection in urban public hospitals in China is projected to be approximately 306 million yuan in the first half of 2025 [2] - The company has initiated preparatory work for the product's market launch, but there is considerable uncertainty regarding its potential to generate significant revenue in the future [2]